Multiple Patterns of FHIT Gene Homozygous Deletion in Egyptian Breast Cancer Patients by Ismail, Heba M. S. et al.
SAGE-Hindawi Access to Research
International Journal of Breast Cancer
Volume 2011, Article ID 325947, 9 pages
doi:10.4061/2011/325947
Research Article
Multiple Patterns of FHIT GeneHomozygous Deletionin
EgyptianBreastCancerPatients
HebaM. S. Ismail,1 Amina M. Medhat,2 Amr M. Karim,2 andNadiaI.Zakhary1
1Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt
2Biochemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt
Correspondence should be addressed to Heba M. S. Ismail, hmsmbm@gmail.com
Received 16 May 2011; Revised 4 August 2011; Accepted 4 August 2011
Academic Editor: Claudio Luparello
Copyright © 2011 Heba M. S. Ismail et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Fragile histidine triad (FHIT) gene encodes a putative tumour suppressor protein. Loss of Fhit protein in cancer is attributed to
diﬀerent genetic alterations that aﬀect the FHIT gene structure. In this study, we investigated the pattern of homozygous deletion
that target the FHIT gene exons 3 to 9 genomic structure in Egyptian breast cancer patients. We have found that 65% (40 out
of 62) of the cases exhibited homozygous deletion in at least one FHIT exon. The incidence of homozygous deletion was not
associated with patients’ clinicopathological parameters including patients’ age, tumour grade, tumour type, and lymph node
involvement. Using correlation analysis, we have observed a strong correlation between homozygous deletions of exon 3 and exon
4( P<0.0001). Deletions in exon 5 were positively correlated with deletions in exon 7 (P<0.0001), Exon 8 (P<0.027), and
exon 9 (P = 0.04). Additionally, a strong correlation was observed between exons 8 and exon 9 (P<0.0001).We conclude that
FHIT gene exons are homozygously deleted at high frequency in Egyptian women population diagnosed with breast cancer. Three
diﬀerent patterns of homozygous deletion were observed in this population indicating diﬀerent mechanisms of targeting FHIT
gene genomic structure.
1.Introduction
Fragile histidine triad (FHIT) gene located at chromosome
3p14.2 is a putative tumour suppressor gene involved in the
pathogenesis of breast cancer. Both genetic and epigenetic
alterationsinFHIT havebeenimplicatedinbreastcarcinoma
[1–3]. Consistent with its proposed function as a tumour
suppressor, homozygous genomic deletions within the FHIT
genehavebeenobservedinalargenumberofhumancancers
and cancer cell lines. FHIT is a member of histidine triad
(HIT)proteins,whichrepresentasmallfamilyofnucleotide-
binding and hydrolyzing proteins. HIT proteins received
attention of cancer biologists because of their downregulated
expression in multiple human malignancies [4]. FHIT gene
deletion or loss of transcription has been reported in head
and neck [5], gastrointestinal [6, 7], cervical [8], lung [9]
breast, [10, 11], kidney [12], and hematopoietic tumours
[13]. Chromosomal region 3p14.2 is a frequent target for
genetic and cytogenetic alterations in a wide range of solid
tumors [14], leading to the search for a tumour suppressor
gene in this region.
The function of FHIT is directly linked to intracellular
signalling and the DNA damage response [15]. FHIT is
frequently involved in biallelic loss and other chromosome
abnormalities in tumours [16, 17]. FHIT deletions, abnor-
mal transcripts, promoter hypermethylation, and associated
loss of expression are common in human malignancies. In
cancer cells, these events are often associated with deletions
directly within the FRA3B region, centering on exon 5 of
FHIT. A high frequency of heterozygous and homozygous
deletions with breakpoints within the fragile site region of
FHIT has been detected in large number of cancers and
cancer cell lines [5, 18–21]. Corbin et al. [22] showed
multiple, variable deletions in FRA3B, even in cells derived
from the same tumour, suggesting ongoing instability in the
region.
The FHIT locus contains the most fragile site in the
human genome; FRA3B, the papilloma virus integration site,2 International Journal of Breast Cancer
and a familial-kidney-cancer-associated breakpoint t(3;8)
(p14.2;q24) [16, 35]. FHIT gene has 10 small exons extend
over ∼2Mb DNA that make up the 1.1kb cDNA [23].
Exons 5 to 9 are the coding exons that encode a small
protein of 16.8KD mass. Fhit protein is a typical dinucleo-
side 5 ,5   -P1, P3-triphosphate (Ap3A) hydrolase which is
highly homologous to Ap4A (diadenosine tetraphosphate)
hydrolase from Schizosaccharomyces pombe. The Fhit protein
exerts its oncosuppressor activity through induction of
an apoptotic mechanism that seems to be Fas-associated
death domain (FADD) dependent, caspase-8 mediated, and
independent from mitochondrial ampliﬁcation [24]. Loss
of Fhit protein in cancer is attributed to diﬀerent genetic
alterations that aﬀect FHIT gene structure. In tumour-
derived cell lines, homozygous deletions that result from
the loss of genomic regions containing or surrounding the
relevant FHIT e x o n sl e a dt on u m e r o u sa b n o r m a lt r a n s c r i p t s
that included the absence of various regions between exon
4 and 9, while the mRNAs of the corresponding normal
tissues did not exhibit these alterations [16]. None of the
truncated transcripts can encode a fully functional protein.
In addition to homozygous deletion, FHIT gene structure is
also subjected to loss of heterozygosity (LOH) and promoter
hypermethylation [25]. The signiﬁcant association of FHIT
mutationandhypermethylationleadstothecompleteinacti-
vation of FHIT gene in patients with breast cancer. Silencing
of the FHIT gene by promoter hypermethylation occurs
in breast carcinomas, especially those with the signiﬁcant
amount of mutations in its genomic structure [26]. FHIT
gene methylation was also reported in serum of sporadic
breast cancer in a CpG island methylator phenotype (CIMP)
screening [27].
Despite the extensive analysis of FHIT gene in cancer
cells, the studies on primary malignant tissues are limited.
Here we aimed to understand the genetic alterations that
aﬀect FHIT gene in an Egyptian population of primary
breast cancer patients. Recently, we have reported loss of
heterozygosity (LOH) in FHIT gene locus and its ﬂanking
region on chromosome 3p in Egyptian breast cancer patients
[28]. To extend the analysis of FHIT gene locus in this
population, we investigated the incidence of homozygous
deletion that targets the FHIT gene exons and the correlation
between observed deletions. Furthermore, we investigated
the association between these deletions and the patients’
clinicopathological data.
2.MaterialsandMethods
2.1. Patients. Paired normal and tumour tissues were
obtained from 62 patients diagnosed with breast carcinomas
prior to therapy at the National Cancer Institute (Cairo,
Egypt). Matched normal tissue samples were obtained from
the tumour safety margin. The study was approved by the
review board of the institution. The specimens collected and
used in the study were obtained under each patient’s consent
along with approval. The patients were staged according
to the TNM Staging System [29]. The patients’ clinic-
pathological parameters are summarised in Table 1.
2.2. DNA Extraction. DNA extraction from the tumour and
safety margin tissues obtained from patients was performed
using QIAamp DNA Minikit method (Qiagen, Germany)
as described in the manufacturer’s protocol. This method
depends on degradation of the proteins and cell membranes
using proteinase K enzyme, precipitation of DNA by ethanol
(96–100%) followed by puriﬁcation of DNA using QIAamp
spin columns. The retained DNA is ﬁnally eluted from the
membrane using TE buﬀer.
2.3. Homozygous Deletion Analysis. Patients DNAs were
examined for homozygous deletion in FHIT exons. In
brief, PCRs were performed with 8 diﬀerent primers cor-
responding to exons 3 to 9, and β-actin was used as a
control. Exon-speciﬁc primers used in this study are listed
in Table 2. PCR ampliﬁcation was performed in a 12.5μL
reaction volume using 1× PCR buﬀer (Invitrogen), 1.5mM
MgCl2 (Invitrogen), 0.2mM of each dNTP, 20ng of each
primer, 0.5 unit Taq polymerase (Invitrogen), and 100ng
template DNA. The reaction mixture was ampliﬁed using
Perkin Elemer thermal cycler. Cycling conditions were 94◦C
for 2min followed by 30 cycles at 94◦C for 30s, 57◦C
f o r3 0 s ,a n daﬁ n a le x t e n s i o ns t e pa t7 2 ◦Cf o r7m i n .
PCR products were then electrophoresed onto 2% agarose
gel stained with ethidium bromide and visualized under
UV transilluminator. Homozygous deletions were evaluated
by comparing bands of exons in tumour samples with
their matched normals. Exon bands that showed signiﬁcant
reduction compared to normal were considered positive for
HD.
2.4. Statistical Analysis. The results were analysed using
GraphPad prism computer system (GraphPad software, San
Diego, CA). Pearson correlation analysis was used to test
the correlation between exons in the context of homozygous
deletion. Chi-square and Fisher exact tests were used to
test the association between or HD deletions with each of
patients’clinicopathologicalparameters.Theassociationwas
considered signiﬁcant when P ≤ 0.05.
3. Results
3.1. FHIT Exons Are Subjected to Homozygous Deletion in
Breast Cancer Patients. FHIT gene has 10 small exons that
make up the 1.1-kb cDNA [23] .E x o n s3 ,4 ,a n d5a r e
present in close proximity to the familial kidney-tumour-
associated t (3; 8) translocation break, including the HPV16
integration site identiﬁed in cervical carcinoma, and the
fragile sites in intron 5. Out of 10 exons, the ﬁrst four exons
and the last exon are noncoding exons; therefore, exon 5 is
the ﬁrst coding exon of the FHIT gene which has the initial
methionine codon of the FHIT open reading frame (ORF),
thatextendstoexon9andencodesasmallproteinof16.8KD
mass. while exon 8 encodes the histidine triad motif [16].
To investigate the incidence of homozygous deletion in
FHIT gene exons in Egyptian patients diagnosed with breast
cancer, we performed exon-speciﬁc PCRs for coding exons 5
to 9. Additionally, we investigated noncoding exons 3 and 4.International Journal of Breast Cancer 3
Table 1: Patients clinicopathological features.
Sample no. Age Tumour type Grade (G) Lymph node status
17 7I D CG 2 0 / 5
24 7I D CG 2 0 / 9
3 52 IDC G2 0/12
46 2I D CG 2 0 / 8
5 40 ILC NI 18/18
6 NI Angiosarcoma G3 3/19
75 2I D CG 2 6 / 6
8 50 ILC NI 7/9
9 42 IDC G2 3/12
10 35 IDC G2 2/13
11 40 IDC G2 5/14
12 40 ILC NI 3/14
13 55 IDC G2 NI
14 38 IDC G2 5/8
15 50 IDC G2 17/19
16 42 IDC G2 0/17
17 NI IDC G3 NI
18 50 ILC NI 0/13
19 58 IDC G3 14/15
20 41 IDC G2 4/11
21 46 IDC G3 0/19
22 42 IDC G2 2/13
23 50 ILC NI 7/7
24 44 IDC G3 0/12
25 55 IDC G2 5/12
26 41 IDC G3 0/24
27 34 IDC G2 9/12
28 53 IDC G2 0/9
29 75 IDC G2 0/7
30 55 Comedocarcinoma NI NI
31 NI IDC G2 NI
32 60 IDC G2 0/16
33 50 IDC G3 11/13
34 42 IDC G3 6/22
35 70 IDC G2 3/17
36 45 Adenocarcinoma NI 1/14
37 61 IDC G2 5/18
38 NI IDC NI 0/10
39 58 IDC G3 0/8
40 52 IDC G2 1/7
41 42 IDC G2 1/15
42 55 IDC G2 1/13
43 35 IDC G2 15/15
44 45 IDC G2 0/12
45 40 IDC G2 11/18
46 55 IDC G2 6/22
47 40 IDC G3 11/20
48 35 IDC G3 6/104 International Journal of Breast Cancer
Table 1: Continued.
Sample no. Age Tumour type Grade (G) Lymph node status
49 55 IDC G2 4/15
50 34 IDC G2 4/11
51 50 IDC G3 1/13
52 65 IDC G2 5/8
53 62 IDC G2 4/15
54 42 IDC G3 0/10
55 40 ILC G1 NI
56 NI IDC NI NI
57 50 Medullary carcinoma NI NI
58 35 IDC G3 4/12
59 40 IDC G3 6/22
60 73 Gynecomastia∗ NI NI
61 42 IDC∗ G2 5/12
62 44 ILC G1 NI
IDC: invasive ductal carcinoma, ILC: invasive lobular carcinoma, and NI: no information.
∗Male patients.
Table 2: Sequence of primers used in this study.
Exon Sequence Expected size (BP)
Exon 3 3F: 5  AGGGTGATACTAGCTGCTTT 3 
284
3R: 5  TGACTTTAGCCAGTGGCA 3 
Exon 4 4F: 5  TTGTACCTAGAGCCATCTGG 3 224
4R: 5  GGATACTCACAGCAGGTCAA 3 
Exon 5 5F: 5  TGAGGACATGTCGTTCAGATTT 3 
255
5R: 5  CTGGTGTCTCCGAAGTGGGAGGG 3 
Exon 6 6F: 5  ATGTTCTTGTGTGCCCGCTGCGGCCAGT 3 
147
6R: 5  CTGCATGGAAAAGGTGAGAGAGGTCCCATG 3 
Exon 7 7F: 5  TGGTCCCCATGAGAATACTATAAATTAACA 3 
305
7R: 5  TTACGGCTCTAACACTGAGGGTCTCTCTGA 3 
Exon 8 8F: 5  GAGTAATTGGGCTTCATGAGAGCATCACT 3 
225
8R: 5  AGGTTGATGTCATCCCACCGACAGT 3 
Exon 9 9F: 5  TTCTCCAAAGCTCCAGAAACATGACAAGGA 3 
119
9R: 5  GTCTTTACCTGTGTCACTGAAAGTAGACCC 3 
β-actin F: 5  TCATCACCAATTGGCAATGAG 3 
147
R: 5  CACTGTGTTGGCGTACAGGT 3 
A total of 62 breast cancer patients were investigated for
homozygous deletion (HD) in FHIT exons. Tumour DNA
was compared to its matching normal DNA samples isolated
from the tumour safety margin. We found that 65% of the
cases (40 out of 62) showed HD in at least one of the seven
examined exons. Percentage of HD in the examined exons
is as follows: exon 3: 32.3% (20/62), exon 4: 27.4% (17/62),
exon 5: 29% (18/62), exon 6: 34% (21/62), exon 7: 29%
(18/62), exon 8: 29% (18/62), exon 9: 30.6% (19/62). We
have observed that the samples which exhibited HD in exon
8 were also positive for HD in exon 9. Furthermore, 95%
of samples that showed HD in exon 4 were also positive for
HD in exon 3. Moreover, 29% of the total samples exhibited
deletions in the exons cluster from 5 to 7. Figure 1(a) shows
representative samples that exhibited HD in the investigated
exons. Cases no. 7, 10, and 12 showed HD in exons 5 and 7
in tumour samples compared to their normal counterparts,
while cases 13 and 14 showed intact exons in normal and
tumour samples. Cases no. 30, 31, 32, and 37 exhibited HD
in exons 8 and 9 in tumour samples compared with their
normal counterparts. Case no. 37 exhibited HD in exons 3
and4,whileexon6isintactcomparedtoitsmatchednormal.
Caseno.32showedintactexons3,4and6.Figure 1(b)shows
the incidence of HD in FHIT exons in individual breast
cancer patients. A summary of HD percentages in FHIT
e x o n si ss h o w ni nFigure 1(c).
From these data, we conclude that homozygous deletion
or HD of FHIT gene exons occurs at high frequency inInternational Journal of Breast Cancer 5
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Figure 1: FHIT gene exons are subjected to homozygous deletions in Egyptian neoplastic and preneoplastic breast tissues. DNA was
extracted from breast cancer and matched normal tissue samples then subjected to PCR analysis of FHIT exons. (a) Ampliﬁcation of exons
3, 4, 5, 6, 7, 8, and 9. β-actin was used as a control for equal amount of DNA used in the ampliﬁcation. Intensity of ampliﬁed band in tumour
(T) samples was compared with its relative one in normal sample (N). Samples that showed signiﬁcant reduction or loss of the ampliﬁed
exons were considered positive for exon homozygous deletion (HD). (b) Cumulative data of HD in individual patients. (C) Incidence of HD
of FHIT exons in breast cancer patients. (c) Incidence of HD of FHIT exons in breast cancer patients. (d) Association between HD of FHIT
exons and breast cancer patients’ clinicopathological parameters.
Egyptian breast cancer patients. The high deletion rate
indicatesthatFHIT geneissubjectedtointragenicbreaksand
rearrangementsandhomozygousdeletionofFHIT geneisan
important event in breast carcinogenesis.
3.2.AssociationbetweenHomozygous DeletionsofFHITExons
and Patients’ Clinicopathological Parameters. FHIT exons
deletion in breast cancer samples were compared with
patients’ clinicopathological parameters including tumour
type, tumour grade, patient’s age at diagnosis, and lymph
node status. Results were tested for statistical signiﬁcance
diﬀerence using Chi-square and ﬁsher exact test.
In breast cancer set, no signiﬁcance association was
observed between HD in FHIT exons and patients clinico-
pathological data. Patients younger than 50 years exhibited
HD in 18 out of 29 cases (62%), while 18 out of 27 cases
(67%) showed deletions in patients of ages above 50 years6 International Journal of Breast Cancer
Exon no. Exon 4 Exon 5 Exon 6 Exon 7 Exon 8 Exon 9 Correlation
parameters
Exon 3
0.7991 0.2147 0.8827 0.1627 0.1312 0.1831
<0.0001∗∗∗ <0.0001∗∗∗ 0.1121 0.2308 0.3351 0.1768 P value
Exon 4
0.1250 0.8485 0.06376 0.0375 0.09825 r
0.3587 <0.0001∗∗∗ 0.6406 0.7838 0.4713 P value
Exon 5
0.1886 0.9564 0.3000 0.2702 r
0.1640 <0.0001∗∗∗ 0.0247∗ 0.0440∗ P value
Exon 6
0.1383 0.1061 0.1563 r
0.3095 0.4366 0.2500 P value
Exon 7
0.3315 0.3022 r
0.0126∗ 0.0236∗ P value
Exon 8
0.9579 r
<0.0001∗∗∗ P value
r
Figure 2: Correlation analysis between FHIT exons homozygous deletions. Correlation analysis was done using Pearson and Spearman
correlation tests; “r” is correlation coeﬃcient. Highlighted values represent signiﬁcant positive correlation between the two variables. ∗P<
0.05, ∗∗∗P<0.0001.
old (P = 0.7849). Among the 50 samples diagnosed with
invasive ductal carcinoma type, 32 samples (64%) showed
HD, whereas 8 samples out of 12 (67%) of 12 patients
diagnosed with invasive lobular carcinoma and other types
showed HD (P = 0.8624). Samples’ tumour grades varied
from grade II to III. Out of 35 cases with grade II, 23 (66%)
showed HD while, and 8 out of 14 cases (57%) of grade III
showed HD (P = 0.57). With lymph node status, 10 out
of 17 (59%) showed HD in lymph node negative set, while
in lymph node positive cases 24 out of 37 samples (65%)
showed HD (P = 0.6694).
Taken those data together, we conclude that FHIT gene
could play an important role in breast carcinogenesis, and
its alterations are not restricted with certain features of
the disease. This means that the allelic loss in FHIT gene
structure can occur in breast cancer patients regardless of
patient’s age, tumour grade, tumour type, and lymph node
involvement.
3.3. Classiﬁcation of FHIT Gene Exons Homozygous Deletion
in Breast Cancer Samples. Having identiﬁed the incidence of
HD at each exon in individual patients, we then investigated
the pattern of detected deletions. To achieve that, we
performedstatisticalanalysisofcorrelationbetweenallexons
and the incidence of HD using Pearson and spearman
correlation tests. The spearman correlation coeﬃcient and p
values among investigated exons are shown in Figure 2.
Interestingly, a strong positive correlation was detected
between the HD incidence in the non-coding exons 3 and
4( r = 0.7991, P<0.0001), while there was no correlation
between HD incidence in any of those exons and exons 5, 7,
8, and 9. This can be considered as the ﬁrst deletion cluster.
The second deletion cluster involved exons 5, 6, and 7 a
strong positive correlation was detected between exons 5 and
7( r = 0.9564, P<0.0001) but not 6. Exon 5 deletions were
also positively correlated with deletions in exon 8 and exon 9
(P = 0.02,P = 0.04).Thethirdexondeletionclusterincludes
exons 8 and 9 which showed a signiﬁcant positive correlation
in HD incidence (r = 0.9579, P<0.0001).
From those data we can classify the observed deletions of
FHIT exon into three diﬀerent classes: class I includes exons
3 and 4, class 2 includes exons 5 and 7, and class III includes
thedistalexons8and9.Insomesampleswecanseedeletions
ofexonsfrom5to9.Takenallthoseobservationstogetherwe
concludethatFHIT geneexonsaretargetedbythreediﬀerent
mechanisms that cause homozygous deletions in the exon
clusters.
4. Discussion
Consistent with its proposed function as a tumour suppres-
sor, homozygous genomic deletions within the FHIT gene
have been observed in a large number of human cancers
and cancer cell lines. FHIT is one of the several tumour-
suppressorgenesonchromosome3,whenworkingnormally,
keeping any potentially cancerous cells from growing out of
control. However, when mutations or alterations eliminate
o n eo rb o t hc o p i e so ft h eFHIT gene, the “brakes” that con-
trol cell growth are released, allowing potentially cancerous
lesions to become malignant.
FHIT gene was cloned by Ohta et al. 1996 [16]. Although
the hypothesis that FHIT i sat u m o u rs u p p r e s s o rg e n ew a s
initially met with some scepticism, data in support of this
function have been heavily accumulated. FHIT knockoutInternational Journal of Breast Cancer 7
mice developed spontaneous tumours and are more sus-
ceptible to cancer than wild-type mice. Additionally, Fhit
suppresses tumourigenicity in cancer cell lines which implies
conclusivelythatFHIT isabonaﬁdetumoursuppressorgene
[30]. The presence of the most common fragile site FRA3B
within FHIT suggests that the fragility of this gene makes it
susceptible to rearrangements induced by a variety of envi-
ronmental carcinogens and cancer susceptibility reviewed in
[31].
In the present study, we aimed to investigate the fre-
quency of exon deletions that aﬀect the FHIT gene in a series
of primary breast cancer tumours in Egyptian population.
We then investigated the correlation between all exons
deletions. Furthermore, we sought after the association of
these alterations with patients’ clinicopathological data.
Here, we found that 65% of the breast cancer patients
investigated showed homozygous deletions (HDs) in at least
one FHIT exon (40 out of 62). Deletions percentages in the
coding exons 5–9 were as follows: exon 5: 29% (18/62), exon
6: 34% (21/62), exon 7: 29% (18/62), exon 8: 29% (18/62),
exon 9: 30.6% (19/62). Deletions in the noncoding exons
were observed as follows; exon 3: 32.3% (20/62), exon 4:
27.4% (17/62). This means that coding exons were deleted
in 63% of the investigated samples while noncoding exons
were deleted in about 32% of the cases. The incidence of HD
in our samples was relatively higher than what is reported in
previous studies. This can be attributed to higher frequency
of rearrangements and breaks in the FHIT locus in this
population.
We have noticed that 58% of HD detected in FHIT
gene exons are discontinuous deletions. Simply, deletions in
these samples exhibited a speciﬁc pattern, for example, in
some cases exon 4, 6, 8, and 9 were deleted, while exons
5 and 7 were intact. Discontinuous homozygous deletions
in FHIT gene were reported in previous studies. Various
authors observed this discontinuity of HD in some breast
cell lines [1, 32, 33] which is consistent with our results
in primary breast cancer. Ohta et al. (1996) and Druck et
al. (1997) observed that homozygous deletions can occur
in three or four discontinuous segments in FRA3B, and
frequently involve loss of both copies of speciﬁc FHIT
exons [16, 34]. Overall, this discontinuity can be explained
by the possibility that the mechanism of breakage of the
FRA3B, frequently allows multiple gaps to form on the
same chromosome 3p, which when repaired leave multiple
deletions simultaneously. Most of the deletions described
here are predicted to lead to the truncation of Fhit protein
[35]. It is not necessary that deletions have to occur in all
the FHIT exons, but deletions in any of these exons will
encodeatruncatedproteinwhichmightbefunctionless[20].
In the study of Campiglio et al. 1999, alterations in FHIT
transcripts were detected in 31% of the patients but the
reduction or absence of FHIT protein occurred in 69% of
the breast carcinoma samples [2].
Analysis of FHIT gene in a series of human primary
breastcancerrevealedanalleliclossin25%[1]andabnormal
transcripts in approximately 30% of the cases [36]. FHIT
homozygous deletions in samples with 3p14.2 aberrations
were also found in the benign breast lesions of two women
with familial tendency to breast cancer [37]. Another study
of normal breast epithelium, breast preneoplastic lesions,
and invasive tumors reported the loss of heterozygosity of
the FHIT locus in two patients with intraductal hyperplasia
[38]. We have studied a series of benign breast lesions and
observed a high frequency rate of homozygous deletions in
the noncoding exons (data not shown).
Campiglio et al. [2] analyzed 29 cases of primary breast
tumours for normal and abnormal FHIT transcripts and
for the level of expression of FHIT p r o t e i ni nt h en o r m a l
breast epithelia and breast epithelia tumour of the same
patient. Downmodulation or absence of FHIT protein was
also evaluated in a series of 156 consecutive patients with
primary breast carcinomas. In both groups, FHIT protein
levels were reduced or absent in almost 70% of the breast
cancer samples, whereas aberrant FHIT transcripts were
detected in only 31% of the samples. Moreover, down-
regulation of FHIT protein expression is associated with
highly proliferative and large tumours. Yang et al. suggested
that FHIT gene therapy may potentially be a clinically useful
tool for the treatment of breast cancer [39].
Carefully observing the deletion patterns of FHIT exons
in our samples, we identiﬁed three diﬀerent deletion clusters
based on correlation analysis in this population. First cluster
includes the noncoding exons 3 and 4. We have also observed
that the cluster containing exons 3, 4 was deleted in 29% of
thebreastcancerpatients.Apositivecorrelationwasdetected
between those two exons (r = 0.7991, P<0.0001) this
indicates that this cluster is highly subjected to deletions
in this population. It was reported that this exon cluster is
present in close proximity to the familial-kidney-tumour-
associated t (3;8) translocation break, the cluster of fragile
sites identiﬁed by aphidicolin-induced chromosome breaks
inhuman-hamsterhybridcells.ThisalsoincludestheHPV16
integration site identiﬁed in cervical carcinoma and the
fragile sites in intron 5 in aphidicolin-treated hybrid cells
[16].Thedeletionsweobservecouldbeduetobreaksorviral
integration in that region. Investigation of HPV16 infection
incidence in this primary tumour series could explain why
this region is subjected to deletions. The second deletion
cluster includes exons 5 and 7 which are deleted in 27%
of all samples. We observed a strong positive correlation
w a so b s e r v e db e t w e e nd e l e t i o n si ne x o n5a n de x o n7( r =
0.9564, P<0.0001) but not exon 6. Deletions in exon 5
are expected to aﬀect the gene transcription since it has the
initial methionine codon of the FHIT open reading frame
(ORF), resulting in the loss of the intact ORF [16]. Deletions
in this region could be attributed to the rearrangements and
breaks events that happen due to the presence of the fragile
site FRA3B. The third deletion cluster includes the distal
coding exon 8 and 9 which showed HD in 29% of the total
breast cancer samples investigated. Interestingly, all samples
that showed deletions in exon 8 were also positive for exon
9 deletions (r = 0.9579, P<0.0001). The mechanism
of deletion involving both exons together indicates their
common importance especially exon 8 which ﬂanks the
histidinetriadmotif.Sinceexon8containsthehistidinetriad
domain,itissuggestedthatthisexondeletionscouldresultin
a nonfunctional protein. As a target of deletion, exon 8 could8 International Journal of Breast Cancer
contain an essential function that is lost in carcinogenesis
process. The presence of those three distinguishable deletion
patternsmayreﬂectthediversemechanismsthatcouldtarget
the FHIT gene exons in tumourigenesis.
We also have investigated the association between pa-
tients’ clinic pathological parameters and the HD incidence
in FHIT gene exons. No signiﬁcant association was between
HD in breast cancer patients and their clinicopathological
features as age, lymph node involvement, tumour type, and
tumour grade. This indicates that the deletions if FHIT
exons are not restricted to subcategories of those parameters.
Overall, we show here that FHIT genomic structure
is subjected to extensive allelic alterations represented by
exon homozygous deletion in a series of Egyptian primary
breast cancer. The presence of homozygous deletion of FHIT
exons in breast cancer samples implicates that alteration in
FHIT gene is an important event in breast pathogenenesis in
this population. There was no association between observed
deletions and the patients clinicopathological parameters.
Additionally, we have identiﬁed three diﬀerent patterns of
homozygous deletion which could reﬂect diﬀerent mecha-
nismsthattargetexondeletioninFHIT structure.FHIT gene
is a crucial tumour suppressor gene whose inactivation may
derive clonal expansion of preneoplastic and neoplastic cells
inthebreast.ThepresentﬁndingshighlighttheFHIT geneas
an interesting target for extensive analysis in Egyptian breast
cancer patients.
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